National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK.
Peter J. Barnes
Competing interests statement
The author has served on Scientific Advisory Boards of AstraZeneca, Boehringer-Ingelheim, Chiesi, Daiichi-Sankyo, GlaxoSmithKline, Glenmark, Novartis, Nycomed, Pfizer, Sun Pharmaceuticals, Teva and UCB and has received research funding from Aquinox Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Chiesi, Daiichi-Sankyo, GlaxoSmithKline, Novartis, Pfizer, Prosonix and Takeda. He is also a cofounder of RespiVert (now part of Johnson & Johnson), which has discovered novel inhaled anti-inflammatory treatments for COPD.
Peter Barnes is Head of Respiratory Medicine at Imperial College London, UK, Professor of Thoracic Medicine at the UK's National Heart & Lung Institute and Honorary Consultant Physician at the Royal Brompton Hospital in London, UK. He has published over 1,000 papers in peer-reviewed journals on the mechanisms and treatment of asthma and chronic obstructive pulmonary disease (COPD). Over the past 10 years he has been the most highly cited researcher in the field of COPD. He was elected a fellow of the Royal Society in 2007 and a member of the Academia Europaea in 2012.